July 15, 2013. The company at the time reported federal ANVISA approval of its quality manual and good manufacturing practices, while awaiting certification and registration of several products for its own facilities.
Previously dependent on partners for commercialization and public tenders, the company described this as an important step toward manufacturing and selling its own products. It was also arranging an export partnership in California, with a contract expected the following week. The archived announcement reported FDA status for CHROMA and anticipated broader activity in Latin America. These are historical statements about the company and products at that time, rather than current EVOptica authorizations.